News

October 8, 2018

Recent Formulations of Hormonal Birth Control Reduce Ovarian Cancer Risk, Researchers Report

News

Combined oral contraceptives — containing both smaller doses of estrogens plus newer progestogens — are associated with a decreased risk of ovarian cancer in women younger than 50, a large study ... Read more

October 1, 2018

Extracellular Matrix Changes in Ovarian Cancer Focus of 5-Year Study at University of Wisconsin-Madison

News

Researchers at University of Wisconsin–Madison were awarded a $2.2 million, five-year grant to study the changes that occur in the extracellular matrix — a network of molecules in which cells ... Read more

September 28, 2018

Ovarian Cancer Cells Use Glycogen to Grow, Spread to Other Tissues, Study Shows

News

Ovarian cancer cells are able to use glycogen — a complex sugar molecule used for long-term energy storage — as a source of energy to grow and invade other tissues, ... Read more

September 26, 2018

AIVITA Doses First 10 Ovarian Cancer Patients with Cell-based Immunotherapy in Phase 2 Trial

News

The Phase 2 clinical trial evaluating AIVITA Biomedical’s cell-based immunotherapy for treating newly-diagnosed advanced ovarian cancer has dosed its first 10 patients. The study (NCT02033616) is looking to enroll 99 women at ... Read more

September 24, 2018

Adding Yervoy to Opdivo Increases Responses in Some Ovarian Cancer Patients, Phase 2 Study Shows

News

A combination of Opdivo (nivolumab) and Yervoy (ipilimumab) leads to better response rates in patients with persistent or recurrent ovarian cancer than Opdivo alone, a Phase 2 study shows. The ... Read more

September 21, 2018

Voluntis, AstraZeneca to Test Mobile App Supporting Patients with Platinum-Resistant Ovarian Cancer

News

Voluntis and AstraZeneca have extended their partnership to evaluate a mobile app, called eCO (eCediranib/Olaparib), to help women with platinum-resistant ovarian cancer report and manage their side effects. The approach is being developed for ... Read more

September 19, 2018

Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors

News

IMV will soon launch a Phase 2 trial to examine the potential of its lead candidate DPX-Survivac in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in five solid tumor types. The study is expected ... Read more

September 17, 2018

Two-pronged Antibody Can Help Efficiently Destroy Ovarian Cancer Cells, Researchers Find

News

A newly developed two-pronged antibody is 100 times more effective at destroying ovarian cancer cells than other antibodies in clinical trials, according to researchers at the University of Virginia School ... Read more

September 14, 2018

Celsion Doses First Ovarian Cancer Patient in Phase 1/2 Trial of GEN-1

News

The Phase 1/2 trial evaluating Celsion’s investigational DNA-based immunotherapy GEN-1 as an add-on to standard chemotherapy for localized treatment of ovarian cancer has started dosing patients. GEN-1 is a nanoparticle containing the DNA ... Read more

September 12, 2018

IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient

News

The Phase 1b/2 trial investigating IMV lead candidate DPX-Survivac in combination with Incyte‘s experimental epacadostat and low-dose chemotherapy in recurrent ovarian cancer patients has completed patient enrollment in the study’s first part, the ... Read more